Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Guardant Health Inc GH

Healthcare
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer... see more

Recent & Breaking News (NDAQ:GH)

Guardant Health Announces Preliminary Fourth Quarter and Full Year 2022 Results

Business Wire January 9, 2023

Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Business Wire December 28, 2022

Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy

Business Wire December 21, 2022

Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

Business Wire December 15, 2022

Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer

Business Wire December 8, 2022

Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients

Business Wire December 1, 2022

Guardant Health Reports Third Quarter 2022 Financial Results

Business Wire November 3, 2022

Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022

Business Wire October 10, 2022

Guardant Health Introduces GuardantINFINITY(TM) Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

Business Wire September 9, 2022

Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients

Business Wire September 6, 2022

Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics

Business Wire August 31, 2022

Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference

Business Wire August 29, 2022

Guardant Health Expands Use of Guardant Reveal(TM) Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers

Business Wire August 15, 2022

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca's ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations

Business Wire August 12, 2022

Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit Conference

Business Wire August 8, 2022

Guardant Health and Blueprint Medicines present real-world data identifying EGFR C797X mutation as most common resistance mechanism to osimertinib therapy at IASLC 2022 World Conference on Lung Cancer

Business Wire August 8, 2022

Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM(TM) Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

Business Wire August 5, 2022

Guardant Health Reports Second Quarter 2022 Financial Results

Business Wire August 4, 2022

Guardant Health Receives Medicare Coverage for Guardant Reveal(TM) Test

Business Wire August 2, 2022

Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022

Business Wire July 13, 2022